National Cancer Institute, Division of Cancer Control & Population Sciences. NCI Office of Cancer Survivorship. Accessed September 21, 2020. Available at: https://cancercontrol.cancer.gov/ocs
National Diabetes Statistics Report, 2017. Estimates of diabetes and its burden in the United States. Accessed September 21, 2020. Available at: https://dev.diabetes.org/sites/default/files/2019-06/cdc-statistics-report-2017.pdf
Zaorsky NG, Shaikh T, Ruth K, et al. . Prostate cancer patients with unmanaged diabetes or receiving insulin experience inferior outcomes and toxicities after treatment with radiation therapy. Clin Genitourin Cancer 2017;15:326–335.e3.
Raikundalia MD, Fang CH, Spinazzi EF, et al. . Impact of diabetes mellitus on head and neck cancer patients undergoing surgery. Otolaryngol Head Neck Surg 2016;154:294–299.
Karlin NJ, Kosiorek HE, Castro JC, et al. . Risk of hospitalization in patients with diabetes mellitus who have solid-organ malignancy. Future Sci OA 2016;2:FSO129.
Dąbrowski M, Grondecka A. Diabetes as a risk factor of hospitalization in the surgical ward due to cancer in the elderly and middle-aged population. Arch Med Sci 2017;13:1025–1030.
Barone BB, Yeh HC, Snyder CF, et al. . Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754–2764.
Barone BB, Yeh HC, Snyder CF, et al. . Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010;33:931–939.
Ranc K, Jørgensen ME, Friis S, et al. . Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 2014;57:927–934.
Hoffman KE, McCarthy EP, Recklitis CJ, et al. . Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med 2009;169:1274–1281.
Thong MSY, van de Poll-Franse L, Hoffman RM, et al. . Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int 2011;107:1223–1231.
Yabroff KR, Lawrence WF, Clauser S, et al. . Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 2004;96:1322–1330.
Bowker SL, Pohar SL, Johnson JA. A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health Qual Life Outcomes 2006;4:17.
Shin DW, Ahn E, Kim H, et al. . Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study. Cancer Causes Control 2010;21:919–929.
Tsilidis KK, Kasimis JC, Lopez DS, et al. . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607.
Hwangbo Y, Kang D, Kang M, et al. . Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol 2018;4:1099–1105.
Roeyen G, Jansen M, Chapelle T, et al. . Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study. Pancreatology 2016;16:671–676.
Lohmann AE, Ennis M, Taylor SK, et al. . Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Res Treat 2017;164:451–460.
Cetin M, Colak R, Bayram F, et al. . High prevalence of diabetes in patients with pancreatic cancer in central Anatolia, Turkey. Diabetes Res Clin Pract 2002;58:97–100.
Edwards BK, Noone A-M, Mariotto AB, et al. . Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290–1314.
Paulus YM, Riedel ER, Sabra MM, et al. . Prevalence of diabetes mellitus in patients with newly evaluated papillary thyroid cancer. Thyroid Res 2014;7:7.
Karlin NJ, Dueck AC, Cook CB. Cancer with diabetes: prevalence, metabolic control, and survival in an academic oncology practice. Endocr Pract 2012;18:898–905.
Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013;42:198–201.
Fritz AG, Percy C, Jack A, et al. , eds. International Classification of Diseases for Oncology: ICD-O, 3rd ed, 1st rev. Geneva, Switzerland: World Health Organization; 2013.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care 2019;42(Suppl 1):S13–28.
Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. The Amer Stat 1998;52:119–126.
Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016;25:1029–1036.
Roujun C, Yanhua Y, Bixun L. High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: a hospital based study of 4610 patients with benign tumors or specific cancers. F1000 Res 2016;5:1397.
National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Site recode. Accessed September 21, 2020. Available at: https://seer.cancer.gov/siterecode/
Garg SK, Maurer H, Reed K, et al. . Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 2014;16:97–110.
Hawkins ML, Blackburn BE, Rowe K, et al. . Endocrine and metabolic diseases among colorectal cancer survivors in a population-based cohort. J Natl Cancer Inst 2020;112:78–86.
Flores-Calderón J, Exiga-Gonzaléz E, Morán-Villota S, et al. . Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase. J Pediatr Hematol Oncol 2009;31:790–793.
Yoshida H, Imamura T, Saito AM, et al. . Protracted administration of L-asparaginase in maintenance phase is the risk factor for hyperglycemia in older patients with pediatric acute lymphoblastic leukemia. PLoS One 2015;10:e0136428.
Stamatouli AM, Quandt Z, Perdigoto AL, et al. . Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018;67:1471–1480.
Tzoulis P, Corbett RW, Ponnampalam S, et al. . Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. Endocrinol Diabetes Metab Case Rep 2018;2018:18-0111.
Godwin JL, Jaggi S, Sirisena I, et al. . Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 2017;5:40.
Michie CO, Sakala M, Rivans I, et al. . The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 2010;103:617–621.
Feng JP, Yuan XL, Li M, et al. . Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis 2013;15:27–33.
Milluzzo A, Tumminia A, Vella V, et al. . Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. J Chemother 2019;31:150–159.
Gallo M, Muscogiuri G, Felicetti F, et al. . Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism 2018;78:141–154.
Lipscombe LL, Fischer HD, Yun L, et al. . Association between tamoxifen treatment and diabetes: a population-based study. Cancer 2012;118:2615–2622.
Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. . Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013;31:3076–3082.
Goebel J, Valinski S, Hershey DS. Improving coordination of care among healthcare professionals and patients with diabetes and cancer. Clin J Oncol Nurs 2016;20:645–651.
Walsh J, Young JM, Harrison JD, et al. . What is important in cancer care coordination? A qualitative investigation. Eur J Cancer Care (Engl) 2011;20:220–227.